+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Pharmaceutical Market Size, Share & Trends Analysis Report by Molecule Type, Product, Type, Disease, Formulation, Age Group, Route Of Administration, End Market, Region, and Segment Forecasts, 2023-2030

  • PDF Icon

    Report

  • 250 Pages
  • December 2023
  • Region: Global
  • Grand View Research
  • ID: 5921093
The global pharmaceutical market size is expected to reach USD 2.36 trillion by 2030, expandingat a CAGR of 6.12% from 2023 to 2030. The growth of the pharmaceuticals market is attributable to the increasing prevalence of chronic diseases, leading to a growing need for developing novel therapeutics. According to the National Council on Aging, it is estimated that approximately 95% of the older population has at least one chronic ailment, and around 80% has two or more. Moreover, chronic diseases such as diabetes, arthritis, and heart disease disproportionately affect the elderly population.

Awareness is critical for prevention, early detection, focused therapy, and effective treatment. People aware of an illness and its symptoms are more inclined to take preventative measures, such as screenings, tests, and check-ups. The increased awareness of various diseases is another element driving the pharmaceutical space. As people are now aware of diseases such as cancer and diabetes, they are more likely to seek treatment if they develop those conditions. A number of initiatives are taken by public and private organizations to spread awareness and educate the population. Furthermore, many people now have insurance policies that cover prescription drug expenses, contributing to increased pharmaceutical demand.

Moreover,the demand for pharmaceuticals is significantly increasing globally due to advancements in technology in the development of novel therapeutics. The pharmaceutical industry invests at an unprecedented rate in research and development, as well as product sales and distribution. The industry focuses on distinctly and directly addressing people's health. The pharmaceuticals industry is critical to patient care and community development and provides numerous life-saving treatments, generates employment, and contributes to the world economy.

Many biological agents, such as bacteria and viruses, are used in vaccine manufacturing, fermentation processes, and biotechnology. The market is made up of a diverse spectrum of companies, including giant pharma, mid-sized specialty, virtual pharma, generic manufacturers, and small biotechnology and biopharmaceutical organizations. Furthermore, key players involved in developing and formulating various therapeutic formulations are focusing on collaborations and partnerships to develop novel medications and maintain their competitive position in the market.

Moreover, several players are involved in developing novel pharmaceuticals to meet the rising demand for the prevention and treatment of conditions. For instance, in April 2023, F. Hoffmann-La Roche Ltd. announced that its wet age-related macular degeneration drug, Vabysmo, which received FDA approval in January 2022, brought around USD 500 million during the first quarter of 2023. The drug's sales increased by more than 500% year-on-year, beating competitors such as multiple sclerosis treatment Ocrevus and the hemophilia medication Hemlibra. Moreover, in July 2023, Novartis AG received U.S. FDA approval for an expanded indication of Leqvio (inclisiran), in order to include treatment of patients with high LDL-C who are at an increased risk of heart diseases.

Pharmaceutical Market Report Highlights

  • Based on molecule type, conventional drugs (small molecules) dominated the overall market. Conventional drugs’ dominance in the pharmaceuticals market is due to their well-established manufacturing processes, predictable pharmacokinetics, and oral bioavailability
  • Based on product, the branded segment held the largest revenue share in the pharmaceuticals market in 2022, owing to the presence of several giant pharmaceutical players in the market specializing in branded medication since a long time
  • Based on type, OTC pharmaceuticals are expected to showcase the fastest growth rate over the forecast period owing to the ease of procurement of medication through this channel aided by the reduced need to visit a physician
  • In terms of disease, cancer dominated the pharmaceuticals market in 2022. The dominance of the cancer segment in the market can be attributed to several key factors such as the rising global incidence of various types of cancer, increased demand for innovative & effective treatments, and significant investments and research in this area
  • On the basis of formulation, tablets held the largest revenue share in the pharmaceuticals market in 2022, owing to the ease of administration and greater adoption of this formulation
  • In terms of route of administration, the oral route of administration segment dominated the global market in 2022
  • Based on age group, the adult segment is expected to show fastest growth over the forecast period, owing to the dominance of the adult population globally in the patient pool that consumes various pharmaceuticals
  • In terms of the end market, hospitals dominated the pharmaceuticals industry, underscored by the escalating healthcare demands due to an aging population, increased prevalence of chronic illnesses, and advancements in medical treatments
  • North America held the largest revenue share in 2022, which can be attributed to the developed regional healthcare infrastructure, growing cases of chronic diseases, presence of several key players, and availability of proper and innovative medications in the region


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Pharmaceutical Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Pharmaceutical Market: Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Pharmaceutical Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Dynamics
3.2.1. Market Drivers Analysis
3.2.1.1. Increasing healthcare spending by the government
3.2.1.2. Improving affordability driven by rising per capita income
3.2.1.3. Increasing awareness about healthcare among the population
3.2.1.4. Increasing access to innovative and modern medicines
3.2.1.5. Demographic and lifestyle changes leading to rising prevalence of chronic diseases
3.2.1.6. Rising chronic diseases and geriatric population
3.2.2. Market Restraint Analysis
3.2.2.1. COVID - 19 pandemic
3.2.2.2. Intensification of competition from generic and biosimilar drugs
3.2.2.3. Increasing price - sensitivity of customers for non - reimbursed drugs
3.2.2.4. Increasing barriers to market access and decreasing R&D productivity of pharma companies
3.3. Porter’s Five Forces Analysis
3.4. PESTLE Analysis
Chapter 4. Pharmaceutical Market: Molecule Type Outlook Estimates & Trend Analysis
4.1. Molecule Type Outlook: Movement Analysis
4.2. Biologics & Biosimilars (Large Molecules)
4.2.1. Biologics & Biosimilars Market Estimates And Forecasts, 2018-2030 (USD Billion)
4.2.1.1 Monoclonal Antibodies
4.2.1.2 Monoclonal Antibodies Market Estimates And Forecasts, 2018-2030 (USD Billion)
4.2.2.3 Vaccines
4.2.2.4 Vaccines Market Estimates And Forecasts, 2018-2030 (USD Billion)
4.2.3.5 Cell & Gene Therapy
4.2.3.6 Cell & Gene Therapy Market Estimates And Forecasts, 2018-2030 (USD Billion)
4.2.4.7 Others
4.2.4.8 Others Market Estimates And Forecasts, 2018-2030 (USD Billion)
4.3. Conventional Drugs (Small Molecules)
4.3.1. Conventional Drugs Market Estimates And Forecasts, 2018-2030 (USD Billion)
Chapter 5. Pharmaceutical Market: Product Estimates & Trend Analysis
5.1. Pharmaceutical Market: Product Movement Analysis
5.2. Branded
5.2.1. Branded Product Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
5.3. Generic
5.3.1. Generic Product Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
Chapter 6. Pharmaceutical Market: Type Estimates & Trend Analysis
6.1. Pharmaceutical Market: Type Movement Analysis
6.2. Prescription
6.2.1. Prescription Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
6.3. OTC
6.3.1. OTC Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
Chapter 7. Pharmaceutical Market: Diseases Outlook Estimates & Trend Analysis
7.1. Pharmaceutical Market: Diseases Outlook Movement Analysis
7.2. Cardiovascular diseases
7.2.1. Cardiovascular Diseases Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.3. Cancer
7.3.1. Cancer Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.4. Diabetes
7.4.1. Diabetes Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.5. Infectious diseases
7.5.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.6. Neurological disorders
7.6.1. Neurological Disorders Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.7. Respiratory diseases
7.7.1. Respiratory Diseases Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.8. Autoimmune diseases
7.8.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.9. Mental health disorders
7.9.1. Mental Health Disorders Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.10. Gastrointestinal disorders
7.10.1. Gastrointestinal Disorders Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.11. Women’s Health Diseases
7.11.1. Women’s Health Diseases Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.12. Genetic and Rare genetic diseases
7.12.1. Genetic and Rare Genetic Diseases Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.13. Dermatological conditions
7.13.1. Dermatological Conditions Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.14. Obesity
7.14.1. Obesity Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.15. Renal diseases
7.15.1. Renal Diseases Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.17. Liver conditions
7.17.1. Liver Conditions Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.17. Hematological disorders
7.17.1. Hematological Disorders Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.18. Eye conditions
7.18.1. Eye Conditions Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.19. Infertility conditions
7.19.1. Infertility Conditions Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.20. Endocrine disorders
7.20.1. Endocrine Disorders Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.21. Allergies
7.21.1. Allergies Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
7.22. Others
7.22.1. Others Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
Chapter 8. Pharmaceutical Market: Route of Administration Estimates & Trend Analysis
8.1. Pharmaceutical Market: Route of Administration Movement Analysis
8.2. Oral
8.2.1. Oral Route Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
8.3. Topical
8.3.1. Topical Route Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
8.4. Parenteral
8.4.1. Parenteral Route Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
8.4.1.1. Intravenous
8.4.1.2. Intramuscular
8.5. Inhalations
8.5.1. Inhalations Route Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
8.6. Other
8.6.1. Other Routes Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
Chapter 9. Pharmaceutical Market: Formulation Estimates & Trend Analysis
9.1. Pharmaceutical Market: Formulation Movement Analysis
9.2. Tablets
9.2.1. Tablets Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
9.3. Capsules
9.3.1. Capsules Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
9.4. Injectable
9.4.1. Injectable Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
9.5. Sprays
9.5.1. Sprays Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
9.6. Suspensions
9.6.1. Suspensions Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
9.7. Powders
9.7.1. Powders Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
9.8. Other Formulations
9.8.1. Other Formulations Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
Chapter 10. Pharmaceutical Market: Age Group Estimates & Trend Analysis
10.1. Pharmaceutical Market: Age Group Movement Analysis
10.2. Children & Adolescents
10.2.1. Children & Adolescents Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
10.3. Adults
10.3.1. Adults Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
10.4. Geriatric
10.4.1. Geriatric Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
Chapter 11. Pharmaceutical Market: End Market Estimates & Trend Analysis
11.1. Pharmaceutical Market: End Market Movement Analysis
11.2. Hospitals
11.2.1. Hospitals Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
11.3. Clinics
11.3.1. Clinics Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
11.4. Others
11.4.1. Others Market Revenue Estimates and Forecasts, 2018-2030 (USD Billion)
Chapter 12. Pharmaceutical Market: Regional Business Analysis
12.1. Pharmaceutical Market Share By Region, 2022 & 2030
12.2. North America
12.2.1. North America Pharmaceutical market, 2018-2030 (USD Million)
12.2.2. U.S.
12.2.2.1. Key Country Dynamics
12.2.2.2. Target Disease Prevalence
12.2.2.3. Competitive Scenario
12.2.2.4. Regulatory Framework
12.2.2.5. Reimbursement Scenario
12.2.2.6. U.S. Pharmaceutical market, 2018-2030 (USD MILLION)
12.2.3. Canada
12.2.3.1. Key Country Dynamics
12.2.3.2. Target Disease Prevalence
12.2.3.3. Competitive Scenario
12.2.3.4. Regulatory Framework
12.2.3.5. Reimbursement Scenario
12.2.3.6. Canada Pharmaceutical market, 2018-2030 (USD Million)
12.3. Europe
12.3.1. Europe Pharmaceutical market, 2018-2030 (USD Million)
12.3.2. Germany
12.3.2.1. Key Country Dynamics
12.3.2.2. Target Disease Prevalence
12.3.2.3. Competitive Scenario
12.3.2.4. Regulatory Framework
12.3.2.5. Reimbursement Scenario
12.3.2.6. Germany Pharmaceutical market, 2018-2030 (USD Million)
12.3.3. UK
12.3.3.1. Key Country Dynamics
12.3.3.2. Target Disease Prevalence
12.3.3.3. Competitive Scenario
12.3.3.4. Regulatory Framework
12.3.3.5. Reimbursement Scenario
12.3.3.6. UK Pharmaceutical market, 2018-2030 (USD Million)
12.3.4. France
12.3.4.1. Key Country Dynamics
12.3.4.2. Target Disease Prevalence
12.3.4.3. Competitive Scenario
12.3.4.4. Regulatory Framework
12.3.4.5. Reimbursement Scenario
12.3.4.6. France Pharmaceutical market, 2018-2030 (USD Million)
12.3.5. Italy
12.3.5.1. Key Country Dynamics
12.3.5.2. Target Disease Prevalence
12.3.5.3. Competitive Scenario
12.3.5.4. Regulatory Framework
12.3.5.5. Reimbursement Scenario
12.3.5.6. Italy Pharmaceutical market, 2018-2030 (USD Million)
12.3.6. Spain
12.3.6.1. Key Country Dynamics
12.3.6.2. Target Disease Prevalence
12.3.6.3. Competitive Scenario
12.3.6.4. Regulatory Framework
12.3.6.5. Reimbursement Scenario
12.3.6.6. Spain Pharmaceutical market, 2018-2030 (USD Million)
12.3.7. Denmark
12.3.12.1. Key Country Dynamics
12.3.12.2. Target Disease Prevalence
12.3.12.3. Competitive Scenario
12.3.12.4. Regulatory Framework
12.3.12.5. Reimbursement Scenario
12.3.12.6. Denmark Pharmaceutical market, 2018-2030 (USD Million)
12.3.8. Sweden
12.3.8.1. Key Country Dynamics
12.3.8.2. Target Disease Prevalence
12.3.8.3. Competitive Scenario
12.3.8.4. Regulatory Framework
12.3.8.5. Reimbursement Scenario
12.3.8.6. Sweden Pharmaceutical market, 2018-2030 (USD Million)
12.3.9. Norway
12.3.9.1. Key Country Dynamics
12.3.9.2. Target Disease Prevalence
12.3.9.3. Competitive Scenario
12.3.9.4. Regulatory Framework
12.3.9.5. Reimbursement Scenario
12.3.9.6. Norway Pharmaceutical market, 2018-2030 (USD Million)
12.4. Asia-Pacific
12.4.1. Asia-Pacific Pharmaceutical market, 2018-2030 (USD Million)
12.4.2. Japan
12.4.2.1. Key Country Dynamics
12.4.2.2. Target Disease Prevalence
12.4.2.3. Competitive Scenario
12.4.2.4. Regulatory Framework
12.4.2.5. Reimbursement Scenario
12.4.2.6. Japan Pharmaceutical market, 2018-2030 (USD Million)
12.4.3. China
12.4.3.1. Key Country Dynamics
12.4.3.2. Target Disease Prevalence
12.4.3.3. Competitive Scenario
12.4.3.4. Regulatory Framework
12.4.3.5. Reimbursement Scenario
12.4.3.6. China Pharmaceutical market, 2018-2030 (USD Million)
12.4.4. India
12.4.4.1. Key Country Dynamics
12.4.4.2. Target Disease Prevalence
12.4.4.3. Competitive Scenario
12.4.4.4. Regulatory Framework
12.4.4.5. Reimbursement Scenario
12.4.4.6. India Pharmaceutical market, 2018-2030 (USD Million)
12.4.5. South Korea
12.4.5.1. Key Country Dynamics
12.4.5.2. Target Disease Prevalence
12.4.5.3. Competitive Scenario
12.4.5.4. Regulatory Framework
12.4.5.5. Reimbursement Scenario
12.4.5.6. South Korea Pharmaceutical market, 2018-2030 (USD Million)
12.4.6. Australia
12.4.6.1. Key Country Dynamics
12.4.6.2. Target Disease Prevalence
12.4.6.3. Competitive Scenario
12.4.6.4. Regulatory Framework
12.4.6.5. Reimbursement Scenario
12.4.6.6. Australia Pharmaceutical market, 2018-2030 (USD Million)
12.4.7. Thailand
12.4.7.1. Key Country Dynamics
12.4.7.2. Target Disease Prevalence
12.4.7.3. Competitive Scenario
12.4.7.4. Regulatory Framework
12.4.7.5. Reimbursement Scenario
12.4.7.6. Thailand Pharmaceutical market, 2018-2030 (USD Million)
12.5. Latin America
12.5.1. Latin America Pharmaceutical market, 2018-2030 (USD Million)
12.5.2. Brazil
12.5.2.1. Key Country Dynamics
12.5.2.2. Target Disease Prevalence
12.5.2.3. Competitive Scenario
12.5.2.4. Regulatory Framework
12.5.2.5. Reimbursement Scenario
12.5.2.6. Brazil Pharmaceutical market, 2018-2030 (USD Million)
12.5.3. Mexico
12.5.3.1. Key Country Dynamics
12.5.3.2. Target Disease Prevalence
12.5.3.3. Competitive Scenario
12.5.3.4. Regulatory Framework
12.5.3.5. Reimbursement Scenario
12.5.3.6. Mexico Pharmaceutical market, 2018-2030 (USD Million)
12.5.4. Argentina
12.5.4.1. Key Country Dynamics
12.5.4.2. Target Disease Prevalence
12.5.4.3. Competitive Scenario
12.5.4.4. Regulatory Framework
12.5.4.5. Reimbursement Scenario
12.5.4.6. Argentina Pharmaceutical market, 2018-2030 (USD Million)
12.6. MEA
12.6.1. MEA Pharmaceutical market, 2018-2030 (USD Million)
12.6.2. South Africa
12.6.2.1. Key Country Dynamics
12.6.2.2. Target Disease Prevalence
12.6.2.3. Competitive Scenario
12.6.2.4. Regulatory Framework
12.6.2.5. Reimbursement Scenario
12.6.2.6. South Africa Pharmaceutical market, 2018-2030 (USD Million)
12.6.3. Saudi Arabia
12.6.3.1. Key Country Dynamics
12.6.3.2. Target Disease Prevalence
12.6.3.3. Competitive Scenario
12.6.3.4. Regulatory Framework
12.6.3.5. Reimbursement Scenario
12.6.3.6. Saudi Arabia Pharmaceutical market, 2018-2030 (USD Million)
12.6.4. UAE
12.6.4.1. Key Country Dynamics
12.6.4.2. Target Disease Prevalence
12.6.4.3. Competitive Scenario
12.6.4.4. Regulatory Framework
12.6.4.5. Reimbursement Scenario
12.6.4.6. UAE Pharmaceutical market, 2018-2030 (USD Million)
12.6.5. Kuwait
12.6.5.1. Key Country Dynamics
12.6.5.2. Target Disease Prevalence
12.6.5.3. Competitive Scenario
12.6.5.4. Regulatory Framework
12.6.5.5. Reimbursement Scenario
12.6.5.6. Kuwait Pharmaceutical market, 2018-2030 (USD Million)
Chapter 13. Competitive Landscape
13.1. Company Categorization
13.2. Strategy Mapping
13.2.1. New Product Launch
13.2.2. Partnerships
13.2.3. Acquisition
13.2.4. Collaboration
13.2.5. Funding
13.3. Key Company Market Share Analysis, 2022
13.4. Company Heat Map Analysis
13.5. Company Profiles
13.5.1. F. HOFFMANN - LA ROCHE LTD.
13.5.1.1. Company Overview
13.5.1.2. Financial Performance
13.5.1.3. Product Benchmarking
13.5.1.4. Strategic Initiatives
13.5.2. NOVARTIS AG
13.5.2.1. Company Overview
13.5.2.2. Financial Performance
13.5.2.3. Product Benchmarking
13.5.2.4. Strategic Initiatives
13.5.3. ABBVIE INC.
13.5.3.1. Company Overview
13.5.3.2. Financial Performance
13.5.3.3. Product Benchmarking
13.5.3.4. Strategic Initiatives
13.5.4. JOHNSON & JOHNSON SERVICES, INC.
13.5.4.1. Company Overview
13.5.4.2. Financial Performance
13.5.4.3. Product Benchmarking
13.5.4.13. Strategic Initiatives
13.5.5. MERCK & CO., INC.
13.5.5.1. Company Overview
13.5.5.2. Financial Performance
13.5.5.3. Product Benchmarking
13.5.5.4. Strategic Initiatives
13.5.6. PFIZER INC.
13.5.6.1. Company Overview
13.5.6.2. Financial Performance
13.5.6.3. Product Benchmarking
13.5.6.4. Strategic Initiatives
13.5.7. BRISTOL - MYERS SQUIBB COMPANY
13.5.7.1. Company Overview
13.5.7.2. Financial Performance
13.5.7.3. Product Benchmarking
13.5.7.4. Strategic Initiatives
13.5.8. SANOFI
13.5.8.1. Company Overview
13.5.8.2. Financial Performance
13.5.8.3. Product Benchmarking
13.5.8.4. Strategic Initiatives
13.5.9. GSK PLC
13.5.9.1. Company Overview
13.5.9.2. Financial Performance
13.5.9.3. Product Benchmarking
13.5.9.4. Strategic Initiatives
13.5.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
13.5.10.1. Company Overview
13.5.10.2. Financial Performance
13.5.10.3. Product Benchmarking
13.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 4 Global Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 5 Global Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 6 Global Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 7 Global Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 8 Global Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 9 Global Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 10 Global Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 11 North America Pharmaceutical Market, By Country, 2018-2030 (USD Billion)
Table 12 North America Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 13 North America Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 14 North America Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 15 North America Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 16 North America Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 17 North America Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 18 North America Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 19 North America Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 20 U.S. Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 21 U.S. Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 22 U.S. Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 23 U.S. Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 24 U.S. Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 25 U.S. Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 26 U.S. Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 27 U.S. Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 28 Canada Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 29 Canada Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 30 Canada Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 31 Canada Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 32 Canada Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 33 Canada Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 34 Canada Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 35 Canada Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 36 Europe Pharmaceutical Market, By Country, 2018-2030 (USD Billion)
Table 37 Europe Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 38 Europe Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 39 Europe Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 40 Europe Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 41 Europe Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 42 Europe Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 43 Europe Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 44 Europe Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 45 UK Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 46 UK Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 47 UK Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 48 UK Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 49 UK Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 50 UK Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 51 UK Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 52 UK Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 53 Germany Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 54 Germany Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 55 Germany Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 56 Germany Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 57 Germany Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 58 Germany Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 59 Germany Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 60 Germany Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 61 France Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 62 France Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 63 France Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 64 France Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 65 France Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 66 France Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 67 France Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 68 France Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 69 Italy Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 70 Italy Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 71 Italy Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 72 Italy Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 73 Italy Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 74 Italy Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 75 Italy Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 76 Italy Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 77 Spain Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 78 Spain Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 79 Spain Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 80 Spain Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 81 Spain Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 82 Spain Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 83 Spain Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 84 Spain Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 85 Denmark Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 86 Denmark Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 87 Denmark Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 88 Denmark Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 89 Denmark Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 90 Denmark Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 91 Denmark Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 92 Denmark Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 93 Sweden Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 94 Sweden Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 95 Sweden Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 96 Sweden Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 97 Sweden Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 98 Sweden Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 99 Sweden Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 100 Sweden Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 101 Norway Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 102 Norway Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 103 Norway Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 104 Norway Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 105 Norway Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 106 Norway Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 107 Norway Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 108 Norway Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 109 Asia-Pacific Pharmaceutical Market, By Country, 2018-2030 (USD Billion)
Table 110 Asia-Pacific Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 111 Asia-Pacific Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 112 Asia-Pacific Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 113 Asia-Pacific Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 114 Asia-Pacific Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 115 Asia-Pacific Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 116 Asia-Pacific Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 117 Asia-Pacific Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 118 Japan Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 119 Japan Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 120 Japan Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 121 Japan Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 122 Japan Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 123 Japan Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 124 Japan Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 125 Japan Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 126 China Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 127 China Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 128 China Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 129 China Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 130 China Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 131 China Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 132 China Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 133 China Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 134 India Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 135 India Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 136 India Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 137 India Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 138 India Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 139 India Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 140 India Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 141 India Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 142 South Korea Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 143 South Korea Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 144 South Korea Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 145 South Korea Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 146 South Korea Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 147 South Korea Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 148 South Korea Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 149 South Korea Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 150 Australia Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 151 Australia Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 152 Australia Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 153 Australia Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 154 Australia Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 155 Australia Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 156 Australia Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 157 Australia Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 158 Thailand Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 159 Thailand Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 160 Thailand Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 161 Thailand Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 162 Thailand Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 163 Thailand Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 164 Thailand Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 165 Thailand Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 166 Latin America Pharmaceutical Market, By Country, 2018-2030 (USD Billion)
Table 167 Latin America Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 168 Latin America Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 169 Latin America Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 170 Latin America Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 171 Latin America Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 172 Latin America Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 173 Latin America Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 174 Latin America Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 175 Brazil Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 176 Brazil Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 177 Brazil Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 178 Brazil Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 179 Brazil Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 180 Brazil Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 181 Brazil Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 182 Brazil Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 183 Mexico Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 184 Mexico Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 185 Mexico Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 186 Mexico Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 187 Mexico Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 188 Mexico Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 189 Mexico Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 190 Mexico Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 191 Argentina Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 192 Argentina Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 193 Argentina Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 194 Argentina Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 195 Argentina Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 196 Argentina Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 197 Argentina Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 198 Argentina Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 199 Middle East & Africa Pharmaceutical Market, By Country, 2018-2030 (USD Billion)
Table 200 Middle East & Africa Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 201 Middle East & Africa Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 202 Middle East & Africa Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 203 Middle East & Africa Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 204 Middle East & Africa Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 205 Middle East & Africa Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 206 Middle East & Africa Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 207 Middle East & Africa Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 208 Saudi Arabia Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 209 Saudi Arabia Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 210 Saudi Arabia Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 211 Saudi Arabia Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 212 Saudi Arabia Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 213 Saudi Arabia Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 214 Saudi Arabia Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 215 Saudi Arabia Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 216 South Africa Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 217 South Africa Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 218 South Africa Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 219 South Africa Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 220 South Africa Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 221 South Africa Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 222 South Africa Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 223 South Africa Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 224 UAE Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 225 UAE Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 226 UAE Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 227 UAE Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 228 UAE Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 229 UAE Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 230 UAE Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 231 UAE Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
Table 232 Kuwait Pharmaceutical Market, By Molecule Type, 2018-2030 (USD Billion)
Table 233 Kuwait Pharmaceutical Market, By Product, 2018-2030 (USD Billion)
Table 234 Kuwait Pharmaceutical Market, By Type, 2018-2030 (USD Billion)
Table 235 Kuwait Pharmaceutical Market, By Diseases, 2018-2030 (USD Billion)
Table 236 Kuwait Pharmaceutical Market, By Route of Administration, 2018-2030 (USD Billion)
Table 237 Kuwait Pharmaceutical Market, By Formulation, 2018-2030 (USD Billion)
Table 238 Kuwait Pharmaceutical Market, By Age Group, 2018-2030 (USD Billion)
Table 239 Kuwait Pharmaceutical Market, By End Market, 2018-2030 (USD Billion)
List of Figures
Figure 1 Market Research Process
Figure 2 Information Procurement
Figure 3 Primary Research Pattern
Figure 4 Market Research Approaches
Figure 5 Value Chain - Based Sizing & Forecasting
Figure 6 Market Formulation & Validation
Figure 7 Pharmaceutical Market Segmentation
Figure 8 Market Driver Relevance Analysis (Current & Future Impact)
Figure 9 Market Restraint Relevance Analysis (Current & Future Impact)
Figure 10 Market Challenge Relevance Analysis (Current & Future Impact)
Figure 11 Penetration & Growth Prospect Mapping
Figure 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Figure 13 Porter’s Five Forces Analysis
Figure 14 Pharmaceutical market: Molecule type outlook and key takeaways
Figure 15 Pharmaceutical market: Molecule type movement analysis & market share 2022 & 2030
Figure 16 Biologics & biosimilars (large molecules) market, 2018-2030 (USD Billion)
Figure 17 Conventional drugs (small molecules) market, 2018-2030 (USD Billion)
Figure 18 Pharmaceutical market: Product outlook and key takeaways
Figure 19 Pharmaceutical market: Product movement analysis & market share 2022 & 2030
Figure 20 Branded pharmaceutical market, 2018-2030 (USD Billion)
Figure 21 Generics pharmaceutical market, 2018-2030 (USD Billion)
Figure 22 Pharmaceutical market: Type outlook and key takeaways
Figure 23 Pharmaceutical market: Type movement analysis & market share 2022 & 2030
Figure 24 Prescription pharmaceutical market, 2018-2030 (USD Billion)
Figure 25 OTC pharmaceutical market, 2018-2030 (USD Billion)
Figure 26 Pharmaceutical market: Disease outlook and key takeaways
Figure 27 Pharmaceutical market: Disease movement analysis & market share 2022 & 2030
Figure 28 Cancer market, 2018-2030 (USD Billion)
Figure 29 Cardiovascular diseases market, 2018-2030 (USD Billion)
Figure 30 Diabetes market, 2018-2030 (USD Billion)
Figure 31 Infectious diseases market, 2018-2030 (USD Billion)
Figure 32 Neurological disorders market, 2018-2030 (USD Billion)
Figure 33 Respiratory diseases market, 2018-2030 (USD Billion)
Figure 34 Autoimmune diseases market, 2018-2030 (USD Billion)
Figure 35 Mental health disorders market, 2018-2030 (USD Billion)
Figure 36 Gastrointestinal diseases market, 2018-2030 (USD Billion)
Figure 37 Women’s health diseases market, 2018-2030 (USD Billion)
Figure 38 Genetic and rare genetic diseases market, 2018-2030 (USD Billion)
Figure 39 Dermatological conditions market, 2018-2030 (USD Billion)
Figure 40 Obesity market, 2018-2030 (USD Billion)
Figure 41 Renal diseases market, 2018-2030 (USD Billion)
Figure 42 Liver conditions market, 2018-2030 (USD Billion)
Figure 43 Hemotological disorders market, 2018-2030 (USD Billion)
Figure 44 Eye conditions market, 2018-2030 (USD Billion)
Figure 45 Infertility conditions market, 2018-2030 (USD Billion)
Figure 46 Endocrine disorders market, 2018-2030 (USD Billion)
Figure 47 Allergies market, 2018-2030 (USD Billion)
Figure 48 Other diseases market, 2018-2030 (USD Billion)
Figure 49 Pharmaceutical market: Route of administration outlook and key takeaways
Figure 50 Pharmaceutical market: Route of administration movement analysis & market share 2022 & 2030
Figure 51 Oral pharmaceutical market, 2018-2030 (USD Billion)
Figure 52 Topical pharmaceutical market, 2018-2030 (USD Billion)
Figure 53 Parenteral pharmaceutical market, 2018-2030 (USD Billion)
Figure 54 Inhalations pharmaceutical market, 2018-2030 (USD Billion)
Figure 55 Others pharmaceutical market, 2018-2030 (USD Billion)
Figure 56 Pharmaceutical market: Formulation outlook and key takeaways
Figure 57 Pharmaceutical market: Formulation movement analysis & market share 2022 & 2030
Figure 58 Tablets pharmaceutical market, 2018-2030 (USD Billion)
Figure 59 Capsules pharmaceutical market, 2018-2030 (USD Billion)
Figure 60 Injectables pharmaceutical market, 2018-2030 (USD Billion)
Figure 61 Sprays pharmaceutical market, 2018-2030 (USD Billion)
Figure 62 Suspensions pharmaceutical market, 2018-2030 (USD Billion)
Figure 63 Powders pharmaceutical market, 2018-2030 (USD Billion)
Figure 64 Others formulation pharmaceutical market, 2018-2030 (USD Billion)
Figure 65 Pharmaceutical market: Age group outlook and key takeaways
Figure 66 Pharmaceutical market: Age group movement analysis & market share 2022 & 2030
Figure 67 Children & Adolescents pharmaceutical market, 2018-2030 (USD Billion)
Figure 68 Adults pharmaceutical market, 2018-2030 (USD Billion)
Figure 69 Geriatric pharmaceutical market, 2018-2030 (USD Billion)
Figure 70 Pharmaceutical market: End market outlook and key takeaways
Figure 71 Pharmaceutical market: End movement analysis & market share 2022 & 2030
Figure 72 Hospitals pharmaceutical market, 2018-2030 (USD Billion)
Figure 73 Clinics pharmaceutical market, 2018-2030 (USD Billion)
Figure 74 Others pharmaceutical market, 2018-2030 (USD Billion
Figure 75 Regional Outlook, 2022 & 2030
Figure 76 Regional Market Dashboard
Figure 77 Regional Market Place: Key Takeaways
Figure 78 North America, SWOT Analysis
Figure 79 Europe, SWOT Analysis
Figure 80 Asia-Pacific, SWOT Analysis
Figure 81 Latin America, SWOT Analysis
Figure 82 MEA, SWOT Analysis
Figure 83 North America
Figure 84 North America Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 85 U.S. Key Country Dynamics
Figure 86 U.S. Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 87 Canada Key Country Dynamics
Figure 88 Canada Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 89 Europe
Figure 90 Europe Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 91 UK Key Country Dynamics
Figure 92 UK Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 93 Germany Key Country Dynamics
Figure 94 Germany Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 95 France Key Country Dynamics
Figure 96 France Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 97 Italy Key Country Dynamics
Figure 98 Italy Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 99 Spain Key Country Dynamics
Figure 100 Spain Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 101 Denmark Key Country Dynamics
Figure 102 Denmark Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 103 Sweden Key Country Dynamics
Figure 104 Sweden Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 105 Norway Key Country Dynamics
Figure 106 Norway Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 107 Asia-Pacific
Figure 108 Asia - Pacific Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 109 Japan Key Country Dynamics
Figure 110 Japan Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 111 China Key Country Dynamics
Figure 112 China Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 113 India Key Country Dynamics
Figure 114 India Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 115 Australia Key Country Dynamics
Figure 116 Australia Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 117 Thailand Key Country Dynamics
Figure 118 Thailand Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 119 South Korea Key Country Dynamics
Figure 120 South Korea Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 121 Latin America
Figure 122 Latin America Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 123 Brazil Key Country Dynamics
Figure 124 Brazil Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 125 Mexico Key Country Dynamics
Figure 126 Mexico Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 127 Argentina Key Country Dynamics
Figure 128 Argentina Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 129 MEA
Figure 130 MEA Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 131 South Africa Key Country Dynamics
Figure 132 South Africa Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 133 Saudi Arabia Key Country Dynamics
Figure 134 Saudi Arabia Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 135 UAE Key Country Dynamics
Figure 136 UAE Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 137 Kuwait Key Country Dynamics
Figure 138 Kuwait Market Estimates And Forecast, 2018-2030 (USD Billion)
Figure 139 Strategy Mapping

Companies Mentioned

  • F. HOFFMANN - LA ROCHE LTD.
  • NOVARTIS AG
  • ABBVIE INC.
  • JOHNSON & JOHNSON SERVICES, INC.
  • MERCK & CO., INC.
  • PFIZER INC.
  • BRISTOL - MYERS SQUIBB COMPANY
  • SANOFI
  • GSK PLC
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED

Methodology

Loading
LOADING...

Table Information